Stock analysts at StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a report issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Evogene Price Performance
Evogene stock opened at $1.48 on Friday. The company has a market cap of $7.95 million, a price-to-earnings ratio of -0.33 and a beta of 1.29. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $2.40.
Evogene (NASDAQ:EVGN – Get Free Report) last released its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Articles
- Five stocks we like better than Evogene
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- What is a Secondary Public Offering? What Investors Need to Know
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
